Advertisement

Journal of Neurology

, Volume 261, Issue 7, pp 1405–1412 | Cite as

Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke

  • W. O. Tobin
  • J. A. Kinsella
  • G. F. Kavanagh
  • J. S. O’Donnell
  • R. T. McGrath
  • T. Coughlan
  • D. R. Collins
  • D. O’Neill
  • B. Egan
  • S. Tierney
  • T. M. Feeley
  • R. P. Murphy
  • D. J. H. McCabe
Original Communication

Abstract

The impact of commencing or changing antiplatelet therapy on von Willebrand factor antigen (VWF:Ag) and von Willebrand factor propeptide (VWF:Ag II) levels has not been comprehensively assessed following TIA or ischaemic stroke. In this pilot, longitudinal, observational analytical study, VWF:Ag and VWF:Ag II levels were simultaneously quantified in platelet poor plasma by ELISA in patients within 4 weeks of TIA or ischaemic stroke (baseline), and then 14 days (14d) and >90 days (90d) after altering antiplatelet therapy. Ninety-one patients were recruited. Eighteen were initially assessed on no antiplatelet therapy, and then after 14d (N = 17) and 90d (N = 8) on aspirin monotherapy; 21 patients were assessed on aspirin and after 14d and 90d on clopidogrel; 52 were assessed on aspirin monotherapy, and after 14d and 90d on aspirin and dipyridamole combination therapy. VWF:Ag, VWF:Ag II levels and VWF:Ag/VWF:Ag II ratio were unchanged at 14d and 90d in the overall study population (p ≥ 0.1). VWF:Ag and VWF:Ag II levels remained stable at 14d and 90d after commencing aspirin (p ≥ 0.054), and after changing from aspirin to clopidogrel (p ≥ 0.2). Following the addition of dipyridamole MR to aspirin, there was a significant reduction in VWF:Ag levels at 14d (p = 0.03) and 90d (p = 0.005), but not in VWF:Ag II levels (p ≥ 0.3). The addition of dipyridamole to aspirin led to a persistent reduction in VWF:Ag but not in VWF:Ag II levels, suggesting that dipyridamole may inhibit release of platelet-derived VWF:Ag following TIA or ischaemic stroke.

Keywords

von Willebrand factor von Willebrand factor propeptide TIA Stroke Aspirin Dipyridamole Clopidogrel High on treatment platelet reactivity 

Notes

Acknowledgments

Dr. Tobin’s research was funded by the IICN-Serono Fellowship, Meath Foundation, Lundbeck Neurosciences Bursary programme, and by unrestricted educational grant funding from Merck Serono Ireland, Brennan and Company, Ireland, and Biogen Idec Ireland Limited. Dr. Kinsella’s research was funded by the Stanley Thomas Johnson Foundation, and by unrestricted educational grant funding from Bayer Schering Ireland, Pfizer Ireland and Elitech UK. Dr. Kavanagh’s research was funded by the Health Research Board Ireland. Dr. McCabe’s research programme was part-funded by grant support from the Programme for Research in Third Level Institutions in Ireland (Cycle 4), co-funded by the European Regional Development Fund.

Conflicts of interest

None of the authors report any conflicts of interest or other disclosures. None of the above charities or funding bodies had any influence on study design or conduct, data analysis or interpretation, or had any influence on the decision to submit the final manuscript for publication.

References

  1. 1.
    Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41CrossRefPubMedGoogle Scholar
  2. 2.
    Bath PM, Blann A, Smith N, Butterworth RJ (1998) Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 9:155–159CrossRefPubMedGoogle Scholar
  3. 3.
    Bongers TN, de Maat MPM, van Goor ML, Bhagwanbali V, van Vliet HHDM, Gomez Garcia EB, Dippel DWJ, Leebeek FWG (2006) High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37:2672–2677CrossRefPubMedGoogle Scholar
  4. 4.
    Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ (1997) von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost 77:1104PubMedGoogle Scholar
  5. 5.
    Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, Elalamy I (2004) In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 124:80–85CrossRefPubMedGoogle Scholar
  6. 6.
    De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C (2012) von Willebrand factor: an emerging target in stroke therapy. Stroke 43:599–606PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1–13CrossRefPubMedGoogle Scholar
  8. 8.
    Eisert WG (2001) Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 57:S20–S23CrossRefPubMedGoogle Scholar
  9. 9.
    European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507CrossRefGoogle Scholar
  10. 10.
    Frijns CJ, Kasius KM, Algra A, Fijnheer R, Rinkel GJ (2006) Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 77:863–867PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110:1392–1397CrossRefPubMedGoogle Scholar
  12. 12.
    Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A (2003) Platelet function under aspirin, clopidogrel, and both after ischemic stroke. Stroke 34:849–854CrossRefPubMedGoogle Scholar
  13. 13.
    Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM (2005) Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36:1001–1005CrossRefPubMedGoogle Scholar
  14. 14.
    Hollestelle MJ, Donkor C, Mantey EA, Chakravorty SJ, Craig A, Akoto AO, O’Donnell J, van Mourik JA, Bunn J (2006) von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. Br J Haematol 133:562–569CrossRefPubMedGoogle Scholar
  15. 15.
    Kain K, Catto AJ, Young J, Bamford J, Bavington J, Grant PJ (2002) Increased fibrinogen, von Willebrand factor and tissue plasminogen activator levels in insulin resistant South Asian patients with ischaemic stroke. Atherosclerosis 163:371–376CrossRefPubMedGoogle Scholar
  16. 16.
    Kim HH, Liao JK (2008) Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 28:s39–s42PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Kinsella JA, Tobin WO, Cox D, Coughlan T, Collins R, O’Neill D, Murphy RP, McCabe DJ (2013) Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®). J Stroke Cerebrovasc Dis 22(7):e84–e92CrossRefPubMedGoogle Scholar
  18. 18.
    Kotzailias N, Elwischger K, Sycha T, Rinner W, Quehenberger P, Auff E, Müller C (2007) Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. J Stroke Cerebrovasc Dis 16(5):199–202CrossRefPubMedGoogle Scholar
  19. 19.
    Kozuka K, Kohriyama T, Nomura E, Ikeda J, Kajikawa H, Nakamura S (2002) Endothelial markers and adhesion molecules in acute ischemic stroke–sequential change and differences in stroke subtype. Atherosclerosis 161:161–168CrossRefPubMedGoogle Scholar
  20. 20.
    Leonardi-Bee J, Bath PM, Bousser MG, Davalos A, Diener HC, Guiraud-Chaumeil B, Sivenius J, Yatsu F, Dewey ME (2005) Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 36:162–168CrossRefPubMedGoogle Scholar
  21. 21.
    Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT (2004) Novel diagnostic test for acute stroke. Stroke 35:57–63CrossRefPubMedGoogle Scholar
  22. 22.
    McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM (2005) Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 16:269–280CrossRefPubMedGoogle Scholar
  23. 23.
    McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Purdy G, Lawrie AS, Watt H, Brown MM, Machin SJ (2004) Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack. Br J Haematol 125:777–787CrossRefPubMedGoogle Scholar
  24. 24.
    McCabe DJ, Harrison P, Sidhu PS, Brown MM, Machin SJ (2004) Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 126:861–869CrossRefPubMedGoogle Scholar
  25. 25.
    McCabe DJH, Harrison P, Mackie IJ, Sidhu PS, Purdy G, Lawrie AS, Watt H, Machin SJ, Brown MM (2005) Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis. J Neurol Neurosurg Psychiatry 76:1249–1254PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    McGrath RT, McRae E, Smith OP, O’Donnell JS (2010) Platelet von Willebrand factor—structure, function and biological importance. Br J Haematol 148:834–843CrossRefPubMedGoogle Scholar
  27. 27.
    Nadar SK, Lip GY, Lee KW, Blann AD (2005) Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 94:707–712PubMedGoogle Scholar
  28. 28.
    Nishio K, Anderson PJ, Zheng XL, Sadler JE (2004) Binding of platelet glycoprotein Ib+¦ to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 101:10578–10583PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    R Development Core Team (2012) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, ViennaGoogle Scholar
  30. 30.
    Ruggeri ZM (1997) von Willebrand factor. J Clin Invest 100:S41–S46PubMedGoogle Scholar
  31. 31.
    Serebruany V, Sabaeva E, Booze C, Atar OD, Eisert C, Hanley D (2009) Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. Thromb Haemost 102:538–543PubMedGoogle Scholar
  32. 32.
    Sonneveld MA, van Dijk AC, van den Herik EG, van Loon JE, de Lau LM, van der Lugt A, Koudstaal PJ, de Maat MP, Leebeek FW (2013) Relationship of Von Willebrand factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis 230:210–215CrossRefPubMedGoogle Scholar
  33. 33.
    Tobin WO, Kinsella JA, Coughlan T, Collins DR, O’Neill D, Murphy RP, Egan B, Tierney S, Feeley TM, McCabe DJ (2013) High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study. Eur J Neurol 20:344–352CrossRefPubMedGoogle Scholar
  34. 34.
    Tobin WO, Kinsella JA, Kavanagh GF, O’Donnell JS, McGrath RA, Collins DR, Coughlan T, O’Neill D, Egan B, Tierney S, Feeley TM, Murphy RP, McCabe DJ (2013) Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke. J Neurol 260:590–596CrossRefPubMedGoogle Scholar
  35. 35.
    Tobin WO, Kinsella JA, Collins DR, Coughlan T, O’Neill D, Egan B, Tierney S, Feeley TM, Murphy RP, McCabe DJ (2011) Enhanced ex vivo inhibition of platelet function following addition of dipyridamole to aspirin after transient ischaemic attack or ischaemic stroke: first results from the TRinity AntiPlatelet responsiveness (TrAP) study. Br J Haematol 152:640–647CrossRefPubMedGoogle Scholar
  36. 36.
    van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen PJJ, Fijnheer R (1999) von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 94:179–185PubMedGoogle Scholar
  37. 37.
    Zhao L, Gray L, Leonardi-Bee J, Weaver CS, Heptinstall S, Bath PM (2006) Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 17:100–104CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • W. O. Tobin
    • 1
  • J. A. Kinsella
    • 1
  • G. F. Kavanagh
    • 1
  • J. S. O’Donnell
    • 5
  • R. T. McGrath
    • 5
  • T. Coughlan
    • 2
    • 3
  • D. R. Collins
    • 2
    • 3
  • D. O’Neill
    • 2
    • 3
  • B. Egan
    • 4
  • S. Tierney
    • 4
  • T. M. Feeley
    • 4
  • R. P. Murphy
    • 1
    • 3
  • D. J. H. McCabe
    • 1
    • 3
    • 6
  1. 1.Department of NeurologyThe Adelaide and Meath Hospital, Dublin, Incorporating the National Children’s Hospital, Trinity College DublinDublinIreland
  2. 2.Department of Age-Related Health CareThe Adelaide and Meath Hospital, Dublin, Incorporating the National Children’s Hospital, Trinity College DublinDublinIreland
  3. 3.Department of Stroke ServiceThe Adelaide and Meath Hospital, Dublin, Incorporating the National Children’s Hospital, Trinity College DublinDublinIreland
  4. 4.Department of Vascular SurgeryThe Adelaide and Meath Hospital, Dublin, Incorporating the National Children’s Hospital, Trinity College DublinDublinIreland
  5. 5.Haemostasis Research GroupSt James’s Hospital, Trinity College DublinDublinIreland
  6. 6.Department of Clinical NeurosciencesUCL Institute of NeurologyLondonUK

Personalised recommendations